Literature DB >> 23779114

Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.

Angela J Hanson1, Jennifer L Bayer-Carter, Pattie S Green, Thomas J Montine, Charles W Wilkinson, Laura D Baker, G Stennis Watson, Laura M Bonner, Maureen Callaghan, James B Leverenz, Elaine Tsai, Nadia Postupna, Jing Zhang, Johanna Lampe, Suzanne Craft.   

Abstract

IMPORTANCE: Sporadic Alzheimer disease (AD) is caused in part by decreased clearance of the β-amyloid (Aβ) peptide breakdown products. Lipid-depleted (LD) apolipoproteins are less effective at binding and clearing Aβ, and LD Aβ peptides are more toxic to neurons. However, not much is known about the lipid states of these proteins in human cerebrospinal fluid.
OBJECTIVE: To characterize the lipidation states of Aβ peptides and apolipoprotein E in the cerebrospinal fluid in adults with respect to cognitive diagnosis and APOE ε4 allele carrier status and after a dietary intervention.
DESIGN: Randomized clinical trial.
SETTING: Veterans Affairs Medical Center clinical research unit. PARTICIPANTS: Twenty older adults with normal cognition (mean [SD] age, 69 [7] years) and 27 with amnestic mild cognitive impairment (67 [6] years).
INTERVENTIONS: Randomization to a diet high in saturated fat content and with a high glycemic index (High diet; 45% of energy from fat [>25% saturated fat], 35%-40% from carbohydrates with a mean glycemic index >70, and 15%-20% from protein) or a diet low in saturated fat content and with a low glycemic index (Low diet; 25% of energy from fat [<7% saturated fat], 55%-60% from carbohydrates with a mean glycemic index <55, and 15%-20% from protein). MAIN OUTCOMES AND MEASURES: Lipid-depleted Aβ42 and Aβ40 and apolipoprotein E in cerebrospinal fluid.
RESULTS: Baseline levels of LD Aβ were greater for adults with mild cognitive impairment compared with adults with normal cognition (LD Aβ42, P = .05; LD Aβ40, P = .01). These findings were magnified in adults with mild cognitive impairment and the ε4 allele, who had higher LD apolipoprotein E levels irrespective of cognitive diagnosis (P < .001). The Low diet tended to decrease LD Aβ levels, whereas the High diet increased these fractions (LD Aβ42, P = .01; LD Aβ40, P = .15). Changes in LD Aβ levels with the Low diet negatively correlated with changes in cerebrospinal fluid levels of insulin (LD Aβ42 and insulin, r = -0.68 [P = .01]; LD Aβ40 and insulin, r = -0.78 [P = .002]). CONCLUSIONS AND RELEVANCE: The lipidation states of apolipoproteins and Aβ peptides in the brain differ depending on APOE genotype and cognitive diagnosis. Concentrations can be modulated by diet. These findings may provide insight into the mechanisms through which apolipoprotein E4 and unhealthy diets impart risk for developing AD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23779114      PMCID: PMC3859238          DOI: 10.1001/jamaneurol.2013.396

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  66 in total

Review 1.  Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein.

Authors:  G M Cole; M D Ard
Journal:  Microsc Res Tech       Date:  2000-08-15       Impact factor: 2.769

Review 2.  Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease.

Authors:  Vincenza Frisardi; Vincenzo Solfrizzi; Davide Seripa; Cristiano Capurso; Andrea Santamato; Daniele Sancarlo; Gianluigi Vendemiale; Alberto Pilotto; Francesco Panza
Journal:  Ageing Res Rev       Date:  2010-05-02       Impact factor: 10.895

3.  Amyloid beta oligomers induce impairment of neuronal insulin receptors.

Authors:  Wei-Qin Zhao; Fernanda G De Felice; Sara Fernandez; Hui Chen; Mary P Lambert; Michael J Quon; Grant A Krafft; William L Klein
Journal:  FASEB J       Date:  2007-08-24       Impact factor: 5.191

4.  Chylomicron amyloid-beta in the aetiology of Alzheimer's disease.

Authors:  R Takechi; S Galloway; M M S Pallebage-Gamarallage; J C L Mamo
Journal:  Atheroscler Suppl       Date:  2008-07-18       Impact factor: 3.235

5.  The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma.

Authors:  A Koudinov; E Matsubara; B Frangione; J Ghiso
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

6.  Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.

Authors:  Robert M Koffie; Tadafumi Hashimoto; Hwan-Ching Tai; Kevin R Kay; Alberto Serrano-Pozo; Daniel Joyner; Steven Hou; Katherine J Kopeikina; Matthew P Frosch; Virginia M Lee; David M Holtzman; Bradley T Hyman; Tara L Spires-Jones
Journal:  Brain       Date:  2012-05-26       Impact factor: 13.501

Review 7.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

Review 8.  Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk.

Authors:  R Takechi; S Galloway; M M S Pallebage-Gamarallage; V Lam; J C L Mamo
Journal:  Prog Lipid Res       Date:  2009-11-05       Impact factor: 16.195

9.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

Review 10.  Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01
View more
  42 in total

Review 1.  Body fluid biomarkers in Alzheimer's disease.

Authors:  Huan Lu; Xi-Chen Zhu; Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-04

Review 2.  Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.

Authors:  Marcus O W Grimm; Daniel M Michaelson; Tobias Hartmann
Journal:  J Lipid Res       Date:  2017-05-20       Impact factor: 5.922

3.  High-density lipoprotein mimetic peptide 4F mitigates amyloid-β-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Suresh K Swaminathan; Karunya K Kandimalla; G William Rebeck; Ling Li
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372

4.  APOE ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes.

Authors:  Jing Zhao; Mary D Davis; Yuka A Martens; Mitsuru Shinohara; Neill R Graff-Radford; Steven G Younkin; Zbigniew K Wszolek; Takahisa Kanekiyo; Guojun Bu
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

5.  Differentiating the Influences of Aging and Adiposity on Brain Weights, Levels of Serum and Brain Cytokines, Gastrointestinal Hormones, and Amyloid Precursor Protein.

Authors:  William A Banks; Christine K Abrass; Kim M Hansen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-08-15       Impact factor: 6.053

Review 6.  ATP-binding cassette transporter A1: from metabolism to neurodegeneration.

Authors:  Radosveta Koldamova; Nicholas F Fitz; Iliya Lefterov
Journal:  Neurobiol Dis       Date:  2014-05-17       Impact factor: 5.996

Review 7.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 8.  Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease.

Authors:  Therese S Salameh; Elizabeth M Rhea; William A Banks; Angela J Hanson
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

Review 9.  Peripheral versus central nervous system APOE in Alzheimer's disease: Interplay across the blood-brain barrier.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Wenhui Qu; Ling Li
Journal:  Neurosci Lett       Date:  2019-06-07       Impact factor: 3.046

Review 10.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.